Pharmaceuticals - Austria

  • Austria
  • The revenue in the Pharmaceuticals market in Austria is projected to reach US$3.70bn in 2024.
  • The largest market within the pharmaceuticals industry is Oncology Drugs, with a projected market volume of US$0.63bn in 2024.
  • It is expected that the revenue will experience an annual growth rate (CAGR 2024-2029) of 4.36%, resulting in a market volume of US$4.58bn by 2029.
  • In comparison to other countries worldwide, United States is expected to generate the highest revenue, amounting to US$630.30bn in 2024.
  • Austria's pharmaceutical market is experiencing a surge in demand for natural and homeopathic remedies.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

Austria, known for its scenic beauty and rich culture, has a thriving pharmaceutical market that caters to the needs of its citizens.

Customer preferences:
The Austrian population has a high demand for over-the-counter drugs and dietary supplements. Additionally, there is an increasing trend towards natural and homeopathic remedies. The aging population in Austria has also led to a higher demand for pharmaceutical products related to chronic diseases such as diabetes, hypertension, and cancer.

Trends in the market:
The Austrian pharmaceutical market has been growing steadily over the years. The market is highly regulated, and the government plays a significant role in determining the prices of drugs. The market is dominated by multinational companies, but there has been an increasing trend towards the growth of local companies. The COVID-19 pandemic has led to an increased demand for pharmaceutical products such as vaccines, antivirals, and respiratory drugs.

Local special circumstances:
The Austrian government has implemented measures to regulate drug prices, making it challenging for companies to introduce new drugs at higher prices. The government also encourages the use of generic drugs, which are more affordable for the population. The country also has a well-established healthcare system that ensures that its citizens have access to quality healthcare.

Underlying macroeconomic factors:
Austria has a stable economy with a high standard of living. The country has a highly skilled workforce and a well-developed infrastructure, which makes it an attractive destination for foreign investment. The government's focus on healthcare and the aging population has led to an increased demand for pharmaceutical products. The COVID-19 pandemic has also led to an increased demand for healthcare services and products, which has further boosted the pharmaceutical market in Austria.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Next generation therapy
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)